240 related articles for article (PubMed ID: 38401419)
1. Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Wang H; Tsung A; Mishra L; Huang H
EBioMedicine; 2024 Mar; 101():105031. PubMed ID: 38401419
[TBL] [Abstract][Full Text] [Related]
2. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
[TBL] [Abstract][Full Text] [Related]
3. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
4. Roles of immune dysregulation in MASLD.
Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
[TBL] [Abstract][Full Text] [Related]
5. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
[TBL] [Abstract][Full Text] [Related]
6. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
7. The "Domino effect" in MASLD: The inflammatory cascade of steatohepatitis.
Mladenić K; Lenartić M; Marinović S; Polić B; Wensveen FM
Eur J Immunol; 2024 Apr; 54(4):e2149641. PubMed ID: 38314819
[TBL] [Abstract][Full Text] [Related]
8. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
[TBL] [Abstract][Full Text] [Related]
9. The PD-1/PD-L1 Axis in the Biology of MASLD.
Pipitone RM; Lupo G; Zito R; Javed A; Petta S; Pennisi G; Grimaudo S
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612483
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA
Xie Y; Huang Y; Li ZY; Jiang W; Shi NX; Lu Y; Cao G; Yin Z; Lin XJ
Mol Cancer; 2024 May; 23(1):95. PubMed ID: 38720319
[TBL] [Abstract][Full Text] [Related]
11. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.
Meroni M; Longo M; Dongiovanni P
Front Endocrinol (Lausanne); 2024; 15():1411706. PubMed ID: 38846491
[TBL] [Abstract][Full Text] [Related]
12. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
13. The double roles of T cell-mediated immune response in the progression of MASLD.
Li Z; Wang S; Xu Q; Su X; Wang Y; Wang L; Zhang Y
Biomed Pharmacother; 2024 Apr; 173():116333. PubMed ID: 38479177
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis antagonizing transcription factor-mediated liver damage and inflammation to cancer: Therapeutic intervention by curcumin in experimental metabolic dysfunction associated steatohepatitis-hepatocellular carcinoma.
Srinivas AN; Suresh D; Chidambaram SB; Santhekadur PK; Kumar DP
J Cell Physiol; 2024 Jan; 239(1):135-151. PubMed ID: 37942831
[TBL] [Abstract][Full Text] [Related]
15. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Zhao S; Guo Y; Yin X
Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834
[TBL] [Abstract][Full Text] [Related]
16. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
Targher G; Byrne CD; Tilg H
Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
[TBL] [Abstract][Full Text] [Related]
17. Natural history of metabolic dysfunction-associated steatotic liver disease.
Lekakis V; Papatheodoridis GV
Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
[TBL] [Abstract][Full Text] [Related]
18. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Backer S; Khanna D
Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression.
Piras IS; DiStefano JK
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38565287
[TBL] [Abstract][Full Text] [Related]
20. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38604295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
